News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vertex Pharmaceuticals (MA) (VRTX) Joins GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) in Testing Hepatitis C Combos


11/1/2012 7:00:27 AM

Vertex Pharmaceuticals Inc. (VRTX), maker of the hepatitis C drug Incivek, said it agreed to test one of its experimental therapies for the disease with other drugs from Johnson & Johnson (JNJ) and GlaxoSmithKline Plc. (GSK)

The drug, VX-135, will be tested with J&J’s simeprevir and Glaxo’s GSK2336805 in 12-week trials to determine whether the combinations help rid patients of the virus, Cambridge, Massachusetts-based Vertex said in two statements today. The companies will split development costs with Vertex.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES